Upgrades:
C.H. Robinson Worldwide (NASDAQ:CHRW) was upgraded by equities researchers at Vertical Research from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Monday, PriceTargets.com reports.
A number of other research firms also recently issued reports on CHRW. Evercore ISI began coverage on shares of C.H. Robinson Worldwide in a research note on Monday, September 13th. They issued an "inline" rating and a $95.00 price target for the company. Morgan Stanley increased their price target on shares of C.H. Robinson Worldwide from $58.00 to $60.00 and gave the stock an "underweight" rating in a research note on Thursday, July 8th. Wells Fargo & Company decreased their price target on shares of C.H. Robinson Worldwide from $95.00 to $90.00 and set an "underweight" rating for the company in a research note on Tuesday, July 13th. Zacks Investment Research downgraded shares of C.H. Robinson Worldwide from a "buy" rating to a "hold" rating and set a $94.00 price target for the company. in a research note on Monday, August 2nd. Finally, Citigroup decreased their price target on shares of C.H. Robinson Worldwide from $118.00 to $115.00 and set a "buy" rating for the company in a research note on Wednesday, July 14th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $98.31. Read more …
Eli Lilly and (NYSE:LLY) was upgraded by stock analysts at Berenberg Bank from a "hold" rating to a "buy" rating in a research note issued to investors on Monday, The Fly reports.
A number of other equities research analysts have also recently commented on LLY. Truist assumed coverage on Eli Lilly and in a research note on Tuesday, July 27th. They set a "buy" rating and a $262.00 target price on the stock. DZ Bank upgraded Eli Lilly and from a "hold" rating to a "buy" rating and set a $288.00 price objective on the stock in a research note on Thursday, August 5th. Mizuho boosted their price objective on Eli Lilly and from $250.00 to $279.00 and gave the company a "buy" rating in a research note on Wednesday, August 4th. Truist Securities upped their price target on Eli Lilly and from $225.00 to $262.00 and gave the company a "buy" rating in a research report on Friday, July 2nd. Finally, The Goldman Sachs Group upped their price target on Eli Lilly and from $252.00 to $270.00 and gave the company a "conviction-buy" rating in a research report on Monday, June 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Eli Lilly and presently has a consensus rating of "Buy" and a consensus target price of $257.53. Read more …
3M (NYSE:MMM) was upgraded by stock analysts at Langenberg & Company from a “hold” rating to a “buy” rating in a research report issued on Monday, The Fly reports.
Several other equities analysts also recently weighed in on MMM. Wolfe Research downgraded 3M from a “peer perform” rating to an “underperform” rating and dropped their price objective for the company from $218.00 to $215.00 in a research note on Monday, July 12th. Credit Suisse Group downgraded 3M from an “outperform” rating to a “neutral” rating and raised their price objective for the company from $210.00 to $212.00 in a research note on Tuesday, July 6th. Zacks Investment Research raised 3M from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a research note on Friday, August 6th. JPMorgan Chase & Co. downgraded 3M from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $215.00 to $210.00 in a research report on Monday, October 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on 3M from $196.00 to $201.00 and gave the stock a “hold” rating in a research report on Wednesday, July 28th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $196.54. Read more …
Starbucks (NASDAQ:SBUX) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note issued on Monday, The Fly reports.
A number of other research firms also recently issued reports on SBUX. Barclays raised their price target on shares of Starbucks from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 28th. Wells Fargo & Company assumed coverage on shares of Starbucks in a research report on Sunday, June 20th. They issued a “buy” rating on the stock. Cowen lifted their price objective on shares of Starbucks from $126.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, July 28th. BMO Capital Markets lifted their price objective on shares of Starbucks from $125.00 to $140.00 and gave the company an “outperform” rating in a research report on Wednesday, July 28th. Finally, Jefferies Financial Group lifted their price objective on shares of Starbucks from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, July 28th. Eight equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $126.96. Read more …
